FY2025 Earnings Forecast for ABVX Issued By Lifesci Capital

ABIVAX Société Anonyme (NASDAQ:ABVX) – Equities research analysts at Lifesci Capital lowered their FY2025 EPS estimates for shares of ABIVAX Société Anonyme in a research report issued to clients and investors on Wednesday, June 4th. Lifesci Capital analyst S. Slutsky now expects that the company will post earnings of ($3.68) per share for the year, down from their prior estimate of ($3.14). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share.

ABVX has been the subject of a number of other reports. Morgan Stanley restated an “equal weight” rating and set a $12.00 price target on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reiterated a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th.

ABIVAX Société Anonyme Trading Up 0.9%

ABIVAX Société Anonyme stock opened at $7.87 on Monday. ABIVAX Société Anonyme has a 1-year low of $4.77 and a 1-year high of $14.52. The firm has a 50 day simple moving average of $6.42 and a 200 day simple moving average of $6.87.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of large investors have recently added to or reduced their stakes in the company. abrdn plc grew its stake in shares of ABIVAX Société Anonyme by 34.1% during the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock valued at $3,105,000 after buying an additional 107,750 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $5,336,000. Guggenheim Capital LLC bought a new position in shares of ABIVAX Société Anonyme during the fourth quarter valued at about $92,000. Millennium Management LLC grew its stake in shares of ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after buying an additional 285,542 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of ABIVAX Société Anonyme by 47.5% during the fourth quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company’s stock valued at $141,000 after buying an additional 6,200 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.